Antibody Array for Ovarian Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ovarian cancer screening methods, particularly relying on carcinoma antigen (CA)-125 and imaging, suffer from low specificity and sensitivity, leading to late-stage diagnoses and poor survival rates, highlighting the need for more effective biomarkers for early detection.
Innovation Solution
An antibody array comprising antibodies specific to CA-125, macrophage-stimulating protein (MSP)-α, tissue inhibitor of metalloproteinase (TIMP)-4, alpha-type platelet-derived growth factor (PDGF-Rα), and osteoprotegrin (OPG) is used for detecting ovarian cancer, with a biotin-binding polypeptide for enhanced detection sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CA-125 alone is used for ovarian cancer screening, then the screening process is simple and cost-effective, but the specificity and sensitivity are low leading to late-stage diagnoses
Solution Approach 1:
The patent combines multiple biomarker detection capabilities into a single antibody array system. Five different antibodies targeting CA-125, MSP-α, TIMP-4, PDGF-Rα, and OPG are arranged on one solid support, allowing simultaneous detection of all five biomarkers in one assay. This merging approach resolves the contradiction by achieving high detection accuracy through multi-biomarker analysis while maintaining relative simplicity through a unified platform.
Solution Approach 2:
The antibody array serves multiple functions: it detects five different biomarkers, provides both diagnostic and screening capabilities, and can be applied to various sample types. The single platform performs what would traditionally require multiple separate assays, thereby improving reliability without proportionally increasing complexity.
2Measurement precision
If multiple biomarkers are detected simultaneously, then the detection accuracy and reliability improve, but the device complexity and cost increase
Solution Approach 1:
The antibody array divides the detection task into five distinct functional segments, with each antibody spot dedicated to detecting a specific biomarker. This segmentation allows for precise measurement of each individual biomarker while organizing the complexity into manageable, discrete units on the solid support.
Solution Approach 2:
The patent transitions from sequential single-biomarker detection to parallel multi-biomarker detection by adding the dimension of spatial arrangement. Multiple antibodies are positioned in specific locations on the solid support, enabling simultaneous detection across multiple dimensions rather than requiring sequential testing.
3Reliability
If early detection methods are developed, then the survival rate improves, but the complexity of screening protocols increases
Solution Approach 1:
The antibody array is pre-configured with all necessary antibodies and spatial arrangements before use. The solid support contains pre-positioned antibodies against all five biomarkers, eliminating the need for complex sample preparation or sequential testing procedures. This preliminary preparation maintains ease of operation while enabling comprehensive early detection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody array effectively detects ovarian cancer with high specificity (95%) and sensitivity (100%), significantly improving upon the performance of CA-125 alone, as demonstrated by area under the curve (AUC) values, effectively identifying ovarian cancer patients from healthy controls.
Implementation Method 1
a first antibody or fragment thereof that specifically binds CA-125, a second antibody or fragment thereof that specifically binds MSP-α, a third antibody or fragment thereof that specifically binds TIMP-4, a fourth antibody or fragment thereof that specifically binds PDGF-Rα, and a fifth antibody or fragment thereof that specifically binds OPG
Implementation Method 2
a biotin-binding polypeptide for enhanced detection sensitivity and specificity
Data Source
AI summary
Disclosed are antibody arrays for the detection of cancer in a human or animal subject, comprising a solid support having disposed thereon in a predetermined spatial configuration, a panel of antibodies specific to biomarkers comprising CA-125, MSP-α, TIMP-4, PDGF-Rα and OPG, wherein the panel comprises a first antibody or fragment thereof that specifically binds CA-125, a second antibody or fragment thereof that specifically binds MSP-α, a third antibody or fragment thereof that specifically binds TIMP-4, a fourth antibody or fragment thereof that specifically binds PDGF-Rα, and a fifth antibody or fragment thereof that specifically binds OPG. Also disclosed are systems containing the arrays and methods of using the arrays to detect cancer such as ovarian cancer.